About: Vornorexant

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical.

Property Value
dbo:abstract
  • Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical. Vornorexant has a time to peak of 2.5 hours and a relatively short elimination half-life of 1.3 to 3.3 hours. It was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence. (en)
dbo:casNumber
  • 2265899-49-6
dbo:class
dbo:fdaUniiCode
  • ZY54BP1CK3
dbo:pubchem
  • 137419776
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 68542699 (xsd:integer)
dbo:wikiPageLength
  • 5950 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1084240433 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 23 (xsd:integer)
dbp:casNumber
  • 2265899 (xsd:integer)
dbp:chemspiderid
  • 61751857 (xsd:integer)
dbp:class
dbp:eliminationHalfLife
  • -11880.0
dbp:f
  • 1 (xsd:integer)
dbp:h
  • 22 (xsd:integer)
dbp:iupacName
  • [-2-[[3-pyrazol-1-yl]methyl]-1,3-oxazinan-3-yl]-[5-methyl-2-phenyl]methanone (en)
dbp:n
  • 7 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 137419776 (xsd:integer)
dbp:routesOfAdministration
dbp:smiles
  • CC1=CCCN3CCCO[C@H]3CN4C=CCC5=NC=CF (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • AEZZJXJIJFSUEM-QFIPXVFZSA-N (en)
dbp:synonyms
  • ORN-0829; TS-142 (en)
dbp:unii
  • ZY54BP1CK3 (en)
dbp:width
  • 250 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. It is a dual orexin OX1 and OX2 receptor antagonist (DORA). The medication is taken by mouth. As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical. (en)
rdfs:label
  • Vornorexant (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License